Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company BioMed Valley Discoveries Inc.
DescriptionERK kinase inhibitor
Molecular Target MAP kinase 1 (MAPK1) (ERK-2) ; MAP kinase 3 (MAPK3) (ERK-1)
Mechanism of ActionMAP kinase (p38) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today